Tectonic Therapeutic (TECX) Income from Continuing Operations (2017 - 2026)
Tectonic Therapeutic's (TECX) quarterly Income from Continuing Operations came in at 53803000.0 in Q1 2026, down 236.16% year-on-year from 39513468.32 in Q1 2025, and down 179.85% on a QoQ basis from 19226000.0 in Q4 2025.
Tectonic Therapeutic (TECX) Income from Continuing Operations (2017 - 2026) Analysis & Trends
Tectonic Therapeutic (TECX) has 10 years of Income from Continuing Operations data on file, last reported at 53803000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 236.16% year-over-year to 53803000.0 in Q1 2026; TTM through Mar 2026 was 112048000.0, a 99.14% decrease from a year earlier, with the FY2025 full-year figure at 74151000.0, down 33.65% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 53803000.0, down from 19226000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for TECX reached as high as 9275000.0 in Q4 2023 and fell as low as 53803000.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 20499647.06 across 5 years, with a median of 19035000.0 in 2025.
- Across the five-year window, Income from Continuing Operations surged 63.69% in 2023 and slumped 236.16% in 2026, its largest moves.
- Year by year, Income from Continuing Operations stood at 25540000.0 in 2022, then jumped by 63.68% to 9275000.0 in 2023, then fell by 6.46% to 9874000.0 in 2024, then plunged by 94.71% to 19226000.0 in 2025, then plunged by 179.85% to 53803000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 53803000.0 in Q1 2026, 19226000.0 in Q4 2025, and 19035000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Tectonic Therapeutic | 571.52 Mn | 571.52 Mn | - | -53.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -53.80 Mn |
| Dec 31, 2025 | -19.23 Mn |
| Sep 30, 2025 | -19.04 Mn |
| Jun 30, 2025 | -19.98 Mn |
| Mar 31, 2025 | -16.01 Mn |
| Dec 31, 2024 | -9.87 Mn |
| Sep 30, 2024 | -17.72 Mn |
| Jun 30, 2024 | -12.67 Mn |
| Mar 31, 2024 | -13.23 Mn |
| Dec 31, 2023 | -9.28 Mn |
| Sep 30, 2023 | -11.09 Mn |
| Jun 30, 2023 | -10.64 Mn |
| Mar 31, 2023 | -25.97 Mn |
| Dec 31, 2022 | -25.54 Mn |
| Sep 30, 2022 | -24.02 Mn |
| Jun 30, 2022 | -29.31 Mn |
| Mar 31, 2022 | -31.12 Mn |
| Dec 31, 2021 | -28.31 Mn |
| Sep 30, 2021 | -32.62 Mn |
| Jun 30, 2021 | -37.34 Mn |